Adherence to the new British Society for Rheumatology Psoriatic Arthritis guidelines for anti-tumour necrosis factor therapy

被引：0
|
作者：
Farquhar, K.
Reid, M.
Hanlon, S.
Perry, M. E.
机构：
[1] Royal Alexandra Hosp, Dept Rheumatol, Edmonton, AB, Canada
[2] Inverclyde Royal Hosp, Dept Rheumatol, Greenock, Scotland
来源：
SCOTTISH MEDICAL JOURNAL | 2015年 / 60卷 / 03期
关键词：
Psoriatic arthritis; biologic therapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E14 / E15
页数：2
相关论文
共 50 条
  • [41] Anti-tumour necrosis factor a therapy: can we afford it?
    Symmons, DPM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 969 - 970
  • [42] Problems encountered during anti-tumour necrosis factor therapy
    Desai, Sheetal B.
    Furst, Daniel E.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (04): : 757 - 790
  • [43] Optic neuritis occurring with anti-tumour necrosis factor α therapy
    Simsek, Ismail
    Erdem, Hakan
    Pay, Salih
    Sobaci, Gungor
    Dinc, Ayhan
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1255 - 1258
  • [44] Granuloma annulare induced by anti-tumour necrosis factor therapy
    Voulgari, P. V.
    Markatseli, T. E.
    Exarchou, S. A.
    Zioga, A.
    Drosos, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (04) : 567 - 570
  • [45] Anti-tumour necrosis factor (TNF)-α therapy in undifferentiated spondyloarthropathy
    Schnarr, S
    Kuipers, JG
    Zeidler, H
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (06) : S126 - S129
  • [46] Demyelination during anti-tumour necrosis factor therapy for psoriasis
    Boggs, J. M. E.
    Barnes, L.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (05) : 577 - 578
  • [47] Anti-tumour necrosis factor therapy associated with cutaneous vasculitis
    Livermore, PA
    Murray, KJ
    RHEUMATOLOGY, 2002, 41 (12) : 1450 - 1452
  • [48] Retention on anti-tumour necrosis factor therapy: the Waikato experience
    Ip, Ken
    Hartley, Lorraine
    Solanki, Kamal
    White, Douglas
    NEW ZEALAND MEDICAL JOURNAL, 2015, 128 (1415) : 34 - 40
  • [49] Anti-Tumour Necrosis Factor Therapy for Ulcerative ColitisEvidence to Date
    Chandrashekhar Thukral
    Adam Cheifetz
    Mark A. Peppercorn
    Drugs, 2006, 66 : 2059 - 2065
  • [50] Feasibility of switching anti-tumour necrosis factor-alpha therapy in patients with rheumatois arthritis
    Walsh, C. A. E.
    Minnock, P.
    Slattery, C.
    Kennedy, N.
    Veale, D. J.
    Bresnihan, B.
    FitzGerald, O.
    RHEUMATOLOGY, 2006, 45 : I52 - I52
12345